Meeting Report: Validation of Toxicogenomics-Based Test Systems: ECVAM–ICCVAM/NICEATM Considerations for Regulatory Use
2006

Validation of Toxicogenomics-Based Test Systems

publication Evidence: moderate

Author Information

Author(s): Raffaella Corvi, Hans-Jürgen Ahr, Silvio Albertini, David H. Blakey, Libero Clerici, Sandra Coecke, George R. Douglas, Laura Gribaldo, John P. Groten, Bernd Haase, Karen Hamernik, Thomas Hartung, Tohru Inoue, Ian Indans, Daniela Maurici, George Orphanides, Diana Rembges, Susanna-Assunta Sansone, Jason R. Snape, Eisaku Toda, Weida Tong, Joost H. van Delft, Brenda Weis, Leonard M. Schechtman

Primary Institution: European Centre for the Validation of Alternative Methods (ECVAM)

Hypothesis

What are the principles applicable to the validation of toxicogenomics platforms and specific toxicologic test methods?

Conclusion

The workshop identified key validation principles and recommendations for the future use of toxicogenomics in regulatory decision-making.

Supporting Evidence

  • Toxicogenomics can help identify biological activity of chemicals and drugs.
  • Validation of toxicogenomics methods is essential for regulatory acceptance.
  • Early identification of biomarkers can improve safety assessments.
  • Standardization of methods is necessary to ensure reliability.
  • Collaboration among scientists, regulators, and industry is crucial for progress.

Takeaway

Scientists are figuring out how to use new gene testing methods to make sure they work well and can be trusted for safety assessments.

Methodology

The workshop involved discussions among experts on the validation of toxicogenomics methods and their regulatory implications.

Limitations

The rapid evolution of technology may complicate the validation process.

Digital Object Identifier (DOI)

10.1289/ehp.8247

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication